- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05135559
억제제 유무에 관계없이 혈우병 A 또는 B가 있는 경우 Concizumab이 얼마나 잘 작동하는지에 대한 연구 (Explorer10)
억제제 유무에 관계없이 혈우병 A 또는 B가 있는 12세 미만 어린이에서 콘시주맙 예방의 효능, 안전성 및 약동학을 조사하는 공개 라벨 연구
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
확장된 액세스
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki, 그리스, GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki, 그리스, 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
Gauteng
-
Parktown, Johannesburg, Gauteng, 남아프리카, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Oslo, 노르웨이, 0372
- Klinisk forskningspost
-
-
-
-
-
Beirut, 레바논, 961
- Saint George Hospital University Medical Center
-
Tripoli, 레바논, 1434
- Hospital Nini
-
-
-
-
-
Bucharest, 루마니아, 022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca, 루마니아, 400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea, 루마니아, 410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
-
Vilnius, 리투아니아, LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
Kuala Lumpur
-
Kampung Baru, Kuala Lumpur, 말레이시아, 50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town, Pulau Pinang, 말레이시아, 10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching, Sarawak, 말레이시아, 93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu, Terengganu, 말레이시아, 20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
California
-
San Diego, California, 미국, 92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado Hospital
-
-
Florida
-
Orlando, Florida, 미국, 32806
- Arnold Palmer Children's Hospital
-
Orlando, Florida, 미국, 32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta, Georgia, 미국, 30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah, Georgia, 미국, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, 미국, 70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68114
- Children's Nebraska
-
-
North Carolina
-
Greenville, North Carolina, 미국, 27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus, Ohio, 미국, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston, Texas, 미국, 77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
-
-
-
Banja Luka, 보스니아 헤르체고비나, 78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla, 보스니아 헤르체고비나, 75000
- University Clinical Centre Tuzla
-
-
-
-
-
Skopje, 북 마케도니아, 1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
-
Plovdiv, 불가리아, 4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia, 불가리아, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna, 불가리아, 9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
-
Gothenburg, 스웨덴, 413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Barcelona, 스페인, 08035
- Hospital Vall d'Hebron
-
Madrid, 스페인, 28046
- Hospital Universitario La Paz
-
Málaga, 스페인, 29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar, Murcia, 스페인, 30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
-
Algiers, 알제리, 16000
- Haematology and Blood Bank Department
-
Constantine, 알제리, 25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Tallinn, 에스토니아, 13419
- Tallinn Children's Hospital
-
-
-
-
-
Birmingham, 영국, B4 6NH
- Birmingham Children's Hospital
-
Bristol, 영국, BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London, 영국, WC1N 3HR
- Great Ormond Street Hospital for Children
-
London, 영국, SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
-
-
-
Catania, 이탈리아, 95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence, 이탈리아, 50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova, 이탈리아, 35128
- Azienda Ospedaliera di Padova _
-
Parma, 이탈리아, 43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
Assam
-
Guwahati, Assam, 인도, 781032
- Guwahati Medical College
-
-
Gujarat
-
Surat, Gujarat, 인도, 395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur, Maharashtra, 인도, 416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai, Maharashtra, 인도, 400012
- Seth GS Medical College & KEM Hospital
-
Mumbai, Maharashtra, 인도, 400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai, Maharashtra, 인도, 400066
- MCGM - Comprehensive Thalassemia Care
-
Pune, Maharashtra, 인도, 411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack, Odisha, 인도, 753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur, Rajasthan, 인도, 302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, 인도, 201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow, Uttart Pradesh, 인도, 226014
- SGPGI
-
-
-
-
-
Kanagawa, 일본, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama, 일본, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Bangkok, 태국, 10400
- Ramathibodi Hospital
-
Bangkok, 태국, 10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok, 태국, 10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok, 태국, 10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani, Mueang Distirct,, 태국, 34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana, 터키 (Türkiye), 01130
- Acibadem Adana Hastanesi
-
Adana, 터키 (Türkiye), 01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir, 터키 (Türkiye), 35100
- Ege Universitesi Tip Fakultesi
-
Izmir, 터키 (Türkiye), 35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun, 터키 (Türkiye), 55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun, 터키 (Türkiye), 55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara, Beşevler/Ankara, 터키 (Türkiye), 06500
- Gazi University
-
Ankara, Beşevler/Ankara, 터키 (Türkiye), 06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
-
-
-
Gdansk, 폴란드, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin, 폴란드, 20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw, 폴란드, 02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, 폴란드, 50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
-
Chambéry, 프랑스, 73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre, 프랑스, 94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris, 프랑스, 75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
실험적: Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
기간: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
기간: Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
기간: Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
기간: Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
기간: Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
기간: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
기간: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Clinical Transparency (dept. 2834), Novo Nordisk A/S
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NN7415-4616
- U1111-1247-7330 (기타 식별자: World Health Organization (WHO))
- 2020-000504-11 (EudraCT 번호)
- jRCT2031220097 (레지스트리 식별자: JAPIC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .